Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in participants with cisplatin-ineligible muscle-invasive bladder cancer: an analysis of clinically relevant subgroups in KEYNOTE-905.

Nabil Adra, MD

May 31, 2026, 9:00AM CDT

Abstract & Presentation

Abstract & Presentation

The content displayed at the congress

These materials are for personal use only and not for reproduction.